TYPE 2 DIABETES: WHAT IS THE ROLE OF INSULIN IN NF-KAPPAB, PPARϒ AND CD36 EXPRESSION?
Abstract
In both type II diabetes and insulin-resistance syndromes, vascular complications result from a set of atherogenic processes, involving chronic hyperglycemia, excessive protein glycation (AGEs), nuclear factor kappa-B (NF-kappaB) activation associated with inflammatory cytokines superexpression, oxidative stress altering LDL and scavenger receptor CD36 expression. The contribution of hyperinsulinaemia in this sequence is not completely elucidated. This review adresses the modulation of NF-kappaB, PPAR gamma (PPARγ) and CD36 protein expression by insulin in rat aortic vascular smooth muscle cells (VSMCs) stimulated by AGEs.
Keywords
Type 2 Diabetes; advanced glycation end products; oxidative stress.
Full Text:
PDF (Português (Brasil))DOI: http://dx.doi.org/10.14450/2318-9312.v26.e3.a2014.pp172-178
Refbacks
- There are currently no refbacks.
Copyright (c) 2014 Infarma - Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Infarma - Ciências Farmacêuticas
ISSN - 2318-9312 (Versão eletrônica)
ISSN - 0104-0219 (Versão impressa)
Conselho Federal de Farmácia - CFF
SHIS QI 15 Lote "L" - Lago Sul - Brasília - DF
CEP: 71635-615 - Fone: (61)3878-8751
e-mail:infarma@cff.org.br
Diretoria
Walter da Silva Jorge João, Presidente do Conselho Federal de Farmácia
Lenira da Silva Costa, Vice-Presidente do Conselho Federal de Farmácia
João Samuel de Morais Meira, Tesoureiro do Conselho Federal de Farmácia
Luiz Gustavo de Freitas Pires, Secretário-Geral do Conselho Federal de Farmácia